Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
*Pharming productieovereenkomst met Sanofi
Volgen
*Pharming sluit productieovereenkomst met Sanofi Chimie voor Ruconest (MORE TO FOLLOW) Dow Jones Newswires July 06, 2010 07:02 ET (11:02 GMT)
Er was dus toch voorkennis!!!!
Pharming And Sanofi Chimie Sign Manufacturing Agreement For The Drug Substance Of Ruconest™ Leiden, the Netherlands and Aramon, France, July 6th, 2010. Biotech company Pharming Group NV (“Pharming”) (NYSE Euronext: PHARM) and Sanofi Chimie, wholly owned subsidiary of sanofi-aventis (NYSE Euronext: SAN, NYSE: SNY) announced today the signing of a toll manufacturing agreement to increase the production capacity of the drug substance of Ruconest™, which will improve RuconestTM cost of goods and competitiveness and will put Pharming in the position to satisfy future global demand. Since 2005, Pharming has an ongoing manufacturing agreement with MSD (formerly Schering-Plough/Organon) for the production of RuconestTM. Pharming will launch and supply the markets with material from MSD until the process, up-scaled by Sanofi Chimie, has been validated. In addition, the agreement will enable Pharming to lower cost of goods and will provide Pharming with sufficient production capacity, at one of Sanofi Chimie’s existing manufacturing facilities, to meet future global demands. The financial details of the agreement have not been disclosed. “For the anticipated market launch of RuconestTM this year in Germany and the UK and the further roll-out of the product in the European Economic Area and beyond, we will continue the cooperation with MSD for the supply of RuconestTM,” said Dr. Bruno Giannetti, Chief Operations Officer of Pharming. “Meanwhile, we need to take the next step towards becoming a profitable pharmaceutical company. With a limited investment for technology transfer, we will effectuate the up-scaling of the production process, which will significantly lower cost of goods of RuconestTM.” "Last month’s positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for RuconestTM for the tr eatment of angioedema attacks was a major step towards validation and commercialization of Pharming’s proprietary technology. We are very pleased to be involved in this exciting project," said Francis Carr鬠Chief Executive Officer of Sanofi Chimie. "Pharming is the first European company with a recombinant biopharmaceutical product from this platform to be approved in Europe and we are proud to be able to support the commercialization of this innovative and highly effective product on a world-wide basis.”
en wat gaat dat opleveren deze overeenkomst? The financial details of the agreement have not been disclosed. Dat weten we dus weer niet, zal wel weer voor een appel en een ei zijn.
Pharming And Sanofi Chimie Sign Manufacturing Agreement For The Drug Substance Of Ruconest™ Leiden, the Netherlands and Aramon, France, July 6th, 2010. Biotech company Pharming Group NV (“Pharming”) (NYSE Euronext: PHARM) and Sanofi Chimie, wholly owned subsidiary of sanofi-aventis (NYSE Euronext: SAN, NYSE: SNY) announced today the signing of a toll manufacturing agreement to increase the production capacity of the drug substance of Ruconest™, which will improve RuconestTM cost of goods and competitiveness and will put Pharming in the position to satisfy future global demand. Since 2005, Pharming has an ongoing manufacturing agreement with MSD (formerly Schering-Plough/Organon) for the production of RuconestTM. Pharming will launch and supply the markets with material from MSD until the process, up-scaled by Sanofi Chimie, has been validated. In addition, the agreement will enable Pharming to lower cost of goods and will provide Pharming with sufficient production capacity, at one of Sanofi Chimie’s existing manufacturing facilities, to meet future global demands. The financial details of the agreement have not been disclosed. “For the anticipated market launch of RuconestTM this year in Germany and the UK and the further roll-out of the product in the European Economic Area and beyond, we will continue the cooperation with MSD for the supply of RuconestTM,” said Dr. Bruno Giannetti, Chief Operations Officer of Pharming. “Meanwhile, we need to take the next step towards becoming a profitable pharmaceutical company. With a limited investment for technology transfer, we will effectuate the up-scaling of the production process, which will significantly lower cost of goods of RuconestTM.” "Last month’s positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for RuconestTM for the tr eatment of angioedema attacks was a major step towards validation and commercialization of Pharming’s proprietary technology. We are very pleased to be involved in this exciting project," said Francis Carr�, Chief Executive Officer of Sanofi Chimie. "Pharming is the first European company with a recombinant biopharmaceutical product from this platform to be approved in Europe and we are proud to be able to support the commercialization of this innovative and highly effective product on a world-wide basis.” About Pharming Group NV Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, and nutritional products. On June 24, the European Medicines Agency adopted a positive opinion for Ruconest™ (Rhucin) for the treatment of angioedema attacks. Market Authorization in the European Economic Area is therefore expected to be granted in September 2010. The product is also under development for follow-on indications, i.e. antibody-mediated rejection (AMR) and delayed graft function (DGF) following kidney transplantation. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products, as well as technology in the field of DNA repair (via DNage). Recently the partial spin off of DNage was initiated. Additional information is available on the Pharming website, www.pharming.com. About sanofi-aventis Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). Sanofi Chimie is a wholly owned subsidiary of sanofi-aventis, which deals with active pharmaceutical ingredients manufa cture, both for internal and external purposes. This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements. Contact: Ms. Marjolein van Helmond, T: +31 (0)71 52 47 431 or +31 (0)6 109 299 54, E: m.vanhelmond@pharming.com Sanofi Chimie contact: Mr. Michel Arraou, T: +33 (0) 4 66 57 71 30
Is Pharming hier niet de betalende partij? Appel en een ei zou prima zijn dan.
bandit18 schreef:
Is Pharming hier niet de betalende partij? Appel en een ei zou prima zijn dan.
tja zou ook nog goed kunnen,immers je denkt toch niet dat Sanofi diep in de buidel tast terwijl ze de hele toko v/e appel en ei kunnen hebben,ja toch. Mensen laat jullie niet gek maken...de 0,12 verkopers komen eraan.
bijna nu ff 0,202 0,033 (19,53%) 13:17
De huid wordt vast verkocht? De Beer moet nog geschoten worden in September...
beeldscherm schreef:
[quote=bandit18]
Is Pharming hier niet de betalende partij? Appel en een ei zou prima zijn dan.
[/quote]
tja zou ook nog goed kunnen,immers je denkt toch niet dat Sanofi diep in de buidel tast terwijl ze de hele toko v/e appel en ei kunnen hebben,ja toch.
Mensen laat jullie niet gek maken...de 0,12 verkopers komen eraan.
Hier zit verstand van zaken ;-) Ruud..
With €29,306 million consolidated sales in 2009, sanofi-aventis is one of the world’s leading pharmaceutical companies. A presence in over 100 countries ensures a well-balanced presence between established and emerging markets
Leuk dat MSD ook genoemd wordt!! Dit is een worldwide top 3 farmaceut. Als die zich met het produkt gaat bemoeien dat gaat de handel helemaal goed los (in positieve zin!)
beeldscherm schreef:
[quote=bandit18]
Is Pharming hier niet de betalende partij? Appel en een ei zou prima zijn dan.
[/quote]
tja zou ook nog goed kunnen,immers je denkt toch niet dat Sanofi diep in de buidel tast terwijl ze de hele toko v/e appel en ei kunnen hebben,ja toch.
Mensen laat jullie niet gek maken...de 0,12 verkopers komen eraan.
Hoe vaak moeten die dan nog komen?
GherAhnkAhmon schreef:
De huid wordt vast verkocht? De Beer moet nog geschoten worden in September...
welke beer. om spullen te verkopen moet je het wel produceren en wel voor een goede prijs.
Mundo2 schreef:
[quote=GherAhnkAhmon]
De huid wordt vast verkocht? De Beer moet nog geschoten worden in September...
[/quote]
welke beer.
om spullen te verkopen moet je het wel produceren en wel voor een goede prijs.
dat komt altijd goed wees nu eens verstandig (uitbesteden bestaat ook je kunt niet alles willen en kunnen)
Zou het niet zo zijn dat Sanofi een % van de opbrengst gaat krijgen? Zou voor Pharming niet slecht zijn want dan kost dit up-front geen geld, en zoals we weten heeft Pharming daar niet zoveel van. Nog slimmer zou zijn als ze Sanofi ook de sales en distributie laten doen, die hebben daar tenslotte het apparaat voor. Alleen lees ik daar niets over. Dik
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
AIRBUS
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia Oyj
Nokia OYJ
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)